top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Liver Attenuation.png
Frame 1000008251.jpg
Lung LAI.jpg
lung HAI.jpg
ٍEpicardial Fat .png
coronaryArteryCalcification.png
Thoracic Aorta and Pulmonary Artery Sizing .png
iScreen Shoter - 20261028184534618.jpg
Cardiac Chambers Volumetry.png
iScreen Shoter - 20261028184548151.jpg
aortic.jpg

Comparing AI with Lung-RADS (Version 1.0) for Lung Cancer Detection in Low-Dose CT Surveillance

6 hours ago
2 min read

This study compared AI-based lung cancer likelihood stratification with retrospectively reconstructed Lung-RADS version 1.0 in two baseline low-dose CT screening cohorts: the U.S. National Lung Screening Trial (US-NLST) and the Pamplona International Early Lung Cancer Action Program (P-IELCAP). The primary outcome was histologically confirmed lung cancer within one year.

Study population and approach

The analysis included 2,342 US-NLST examinations with 40 one-year cancers and 3,709 P-IELCAP examinations with 27 one-year cancers. The AI system assigned scans to low-, intermediate-, high-, and highest-likelihood categories. Lung-RADS categories were reconstructed from radiologist-documented nodule information. The supplied manuscript is marked Draft.

Main findings

In US-NLST, the AI high/highest categories included 33 of 40 cancers (82.5%) among 246 scans, with a positive predictive value (PPV) of 13.4%. Lung-RADS category 3 or higher included 30 of 40 cancers among 376 scans (PPV 8.0%). In P-IELCAP, AI high/highest categories included 20 of 27 cancers (74.1%) among 207 scans (PPV 9.7%), compared with 20 of 27 among 390 scans for Lung-RADS category 3 or higher (PPV 5.1%). Both PPV comparisons were reported as statistically significant (p<0.001).

The low-likelihood AI category contained one cancer in each cohort, with observed cancer rates of 0.09% in US-NLST and 0.04% in P-IELCAP. For comparison, Lung-RADS categories 1–2 contained 10 of 40 and 7 of 27 cancers, respectively. AI high/highest categories also identified a portion of cancers retrospectively assigned Lung-RADS 1–2.

Interpretation

The findings suggest that AI stratification may concentrate more one-year cancers in a smaller high-likelihood group and classify fewer cancers as low likelihood than Lung-RADS in these cohorts. The authors note that additional studies are needed to establish clinical utility; the results do not by themselves show that AI-guided screening improves patient outcomes.

Article details

Comparing AI with Retrospectively Reconstructed Lung-RADS for Lung Cancer Detection in Low-Dose CT. Original Research manuscript submitted to Radiology: Cardiothoracic Imaging. The provided PDF is marked Draft; author names and publication details are not included on the available cover page.

Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page